Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Phase 2Active Not RecruitingNCT04557449

Pfizer362 enrolled

Overview

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from the Part 1A will be conducted In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI) In Part 1F, escalating dosed of PF-07220060 will be administered in combination with enzalutamide Part 1B and Part 1C may commence at MTD or before reaching the MTD at a dose level in Part 1A. Part 2A is a dose expansion cohort with fulvestrant and will explore more than one dose of PF-07220060 in participants diagnosed with mBC. Part 2B and Part 2C are expansion for combination therapy of PF-07220060 with letrozole and fulvestrant, respectively. Part 2D is the expansion cohort for combination therapy of PF-07220060 with enzalutamide. Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy. The China monotherapy cohort will evaluate safety, tolerability and PK of PF-07220060 administered as single agent in Chinese participants. The Japan monotherapy cohort will evaluate safety, tolerability and PK of PF-07220060 administered as a single agent in Japanese participants.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Part 1: Breast Cancer (BC) * Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC * Part 1A/Part 1D/Part1E also include: Refractory HR-positive/HER2-positive BC * Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests * Part 1F: prostate cancer * Part 2A, 2B, 2C and 2E: * HR-positive/HER2-negative BC * Patients who are either postmenopausal women or pre/peri-menopausal (Part 2C only) * Part 1D: metastatic castration resistant prostate cancer * Lesion: * Part 1: evaluable lesion (including skin or bone lesion only) * Part 2A, 2B, 2C and 2E: measurable lesion per RECIST v1.1 * Part 2D: Participants with evaluable disease as per PCWG3; participants with bone metastases only are allowed. Participants with biochemical recurrence only are excluded. * Prior systemic Treatment * Part 1: HR-positive/HER2-negative BC * At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator * At least 1 line of anti-endocrine in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease * HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy * Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available * Part 2A and 2E: participants must have received at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed * Part 2B: participants who have not received any prior systemic anti-cancer therapies for advanced/metastatic BC * Part 2C: * Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or * Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal * One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy * Part 2D: * Received prior abiraterone; enzalutamide and CDK4i naive * 0-1 line of chemotherapy is allowed General Inclusion Criteria * All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 * Adequate renal, liver, and bone marrow function Exclusion Criteria: * Part 1D: participants who have had a gastrectomy or have dietary or other restrictions that preclude a 10 hour overnight fast or consumption of the high fat, high calorie meal * Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor * Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway * Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease * Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Major surgery or radiation within 4 weeks prior to study intervention * Last anti-cancer treatment within 2 weeks prior to study intervention * Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry * Pregnant or breastfeeding female participant * Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease

Locations (38)

Ellison Institute

Los Angeles, California, United States

Smilow Cancer Hospital at Yale - New Haven

New Haven, Connecticut, United States

Yale-New Haven Hospital-Yale Cancer Center

New Haven, Connecticut, United States

Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, United States

Brigham & Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Number of participants with dose limiting toxicities in the Dose Escalation Portion

First cycle (28 days) dose limiting toxicities (Parts 1A, 1B, 1C, 1F)

Time frame: Baseline up to day 28 of Cycle 1.

Incidence of clinically significant AEs

Adverse Events

Time frame: Weekly during Cycle 1 and 2 and then every 28 days through study completion, up to approximately 24 months; Each cycle is 28 days

Incidence of clinically significant laboratory assessments

safety laboratory abnormalities

Time frame: Weekly during Cycle 1 and 2 (each cycle is 28 days) and then every 28 days through study completion, up to approximately 24 months

Incidence of clinically significant abnormal vital and ECG parameters

vital signs and heart rate corrected QT interval

Time frame: Day 1, Day 8, Day 15 of Cycle 1 and starting from Cycle 2, and then every 28 days through study completion, up to approximately 24 months (Each cycle is 28 days)

Food Effect

Maximal Concentration, Time to Maximum Plasma Concentration, Area under the Plasma Concentration (Part 1D)

Time frame: Day -7 through the end of Cycle 1

DDI

Maximal Concentration, Time to Maximum Plasma Concentration, Area under the Plasma Concentration (Part 1E)

Time frame: D1 to the end of Cycle 1

Secondary Outcomes

Single Dose: Maximal concentration (Cmax) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Single Dose: Time to Maximum Plasma Concentration (Tmax) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point Within the Dose Interval (AUClast) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero Extrapolated to Infinity (AUCinf) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Apparent Oral Plasma Clearance (CL/F) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Single Dose: Apparent Volume of Distribution (Vz/F) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Steady State Maximal Concentration (Css,max) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Time to Maximum Plasma Concentration at Steady State (Tss,max) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,t) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Steady State Minimum Plasma Concentration (Css,min) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Steady State Apparent Oral Plasma Clearance (CLss/F) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Apparent Volume of Distribution at Steady State (Vss/F) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Terminal Elimination Half-Life (t1/2) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Multiple Dose: Accumulation Ratio (Rac (AUCss,t /AUCsd,t)) in the Dose Escalation and Dose Finding portion

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Tumor Response per RECIST v1.1 and per PCGW3

Per RECIST v1.1 (Part 1 A-E; Part 2B and 2C); per PCWG3 (Part 1F and Part 2D)

Time frame: baseline up to approximately 24 months

Duration of Response (DOR)

Per RECIST v1.1

Time frame: baseline up to approximately 24 months

Progression Free Survival (PFS)

PFS per RECIST v.1.1

Time frame: baseline up to approximately 24 months

Time to Progression (TTP)

TTP per RECIST v1.1

Time frame: baseline up to approximately 24 months

Clinical Benefit Rate (CBR)

CBR per RECIST v1.1 (Parts 2B, 2C)

Time frame: baseline up to approximately 24 months

Peak and Trough Concentration of PF-07220060

Peak and trough concentration (Parts 2B, 2C, 2D)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Peak and trough concentrations of enzalutamide and N-desmethyl enzalutamide

Peak and trough concentrations (Part 2D)

Time frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months

Time to first skeletal events

Time to first skeletal events (Part 2D)

Time frame: Cycle 1 (each cycle is 28 days) to up to approximately 24 months

Quality of life questionnaire

time to functional status deterioration by FACT-P (Part 2D)

Time frame: Cycle 1 (each cycle is 28 days) to up to approximately 24 months

Radiographic Progression Free survival

Part 2D

Time frame: Cycle 1 (each cycle is 28 days) up to approximately 24 months

PSA50

Part 1F and 2D

Time frame: Cycle 1 (each cycle is 28 days) to up to approximately 24 months

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Overview

Conditions

Interventions

Eligibility

Locations (38)

Outcomes

Primary Outcomes

Secondary Outcomes